Back to Search Start Over

Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study

Authors :
Ebru Gul Fidan
Sezer Saglam
Umut Disel
Mehmet Akif Ozturk
Fatih Selcukbiricik
Fatih Kose
Gokhan Demir
Mesut Seker
Cagatay Arslan
Sercan Aksoy
Gokce Temizas
Nil Molinas Mandel
Mustafa Ozguroglu
Yesim Eralp
Taflan Salepci
Mutlu Demiray
Ahmet Bilici
Ibrahim Tek
ŞEKER, Mesut
Publication Year :
2020
Publisher :
American Society of Clinical Oncology, 2020.

Abstract

e13646 Background: Most of the frequent cancers present a large number of very rare targetable genomic alterations. Moreover, some oncogenic drivers are shared across several diseases, and their targeting could improve outcome. We think that testing a large number of genes across all tumor types could improve outcomes in patients with “hard-to-treat” advanced cancers. The most important factor for the cancer patient to benefit from precision medicine therapy is the detection of the targeted driver mutations. The objective of this study is to determine clinical advantages of hybrid capture based comprehensive genomic profiling over classical diagnostic methods in the treatment strategies of patients with advanced stage diverse solid tumors in Turkey. Methods: This study was designed as a national, multicenter, descriptive, non-drug, retrospective cohort study. Study data were collected from medical files of patients. Besides, a survey was conducted to investigate the impact of CGP results on the treatment decisions of the clinicians. Results: The study included the data of 118 patients (55; %46.6 female, 63; %53.4 male). The mean period between the diagnosis and CGP analysis was 748 days. For either due to progression (97; 75.2%) or intolerance to therapy (12; 9.3%), the treatment of some cases was discontinued after CGP analysis. The results of the electronic survey for the clinicians indicated that the 57;48.3% of the clinicians change their treatment approach based on the results of the CGP analysis, of these 24; 42.1% preferred on-label treatments,3; 5.3% clinical trials and the 30; 52.6% preferred off-label treatments. 59;69.8% of the clinicians declared that their patients can reach to the revised treatment. 48;42.1% of the clinicians expressed that CGP support was very important in the last treatment decision. This is the interim descriptive statistics of the study. Conclusions: This is the preliminary results of the study. Conclusions will be done after the final analysis of the study

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....73cd6e5c56c9514a7c6cde168fb7135e